Conclusion/Implications We confirmed that the CSGSA discriminated early-stage EOC with high sensitivity and specificity. It is expected to identify early-stage EOC in asymptomatic women before EOC develops to advanced stage.

PR085/#158 PREDICTORS OF LIFETIME CERVICAL CANCER SCREENING AND ASSOCIATION WITH SOCIAL DETERMINANTS OF HEALTH: CROSS-SECTIONAL EVIDENCE FROM THE CANADIAN LONGITUDINAL STUDY ON AGING

1Melissa Lavecchia*, 2Maura Marcucci, 3Amanda Selk, 4Faminder Raina, 5Valdo Jimenez, 6Andra Nica, 7Julie Nguyen. 1McMaster University, Division of Gynecologic Oncology, Hamilton, Canada; 2McMaster University, General Internal Medicine, Hamilton, Canada; 3University of Toronto, Obst, Toronto, Canada; 4McMaster University, Health Research Methods, Evidence, and Impact, Hamilton, Canada; 5Juravinski Cancer Centre, McMaster University; 6Hamilton, Gynecologic Oncology, Hamilton, Canada

Introduction Cervical cancer screening has resulted in a decrease in the occurrence of and death from cervical cancer. The Canadian Longitudinal Study on Aging (CLSA) prospectively collected health outcomes on >50,000 individuals. We sought to identify the prevalence of Canadian female participants having never undergone cervical cancer screening and the association with social determinants of health.

Methods We performed a cross-sectional analysis from CLSA data. The main outcome was self-report of ever having undergone a pap test. Regression analyses, controlling for the complexity of the design and covariates, evaluated the association between self-reported lifetime cervical cancer screening and social determinants of health.

Results The population-based sample comprised 22,910 participants aged 45–85, of whom 99.8% had available information on cervical cancer screening (n=22,720). The prevalence of never having undergone a pap was 14.1%; weighted prevalence, 11.8% (95%CI 11.0–12.6). Older age (10-year) (OR 1.5, 95%CI 1.4–1.6), lower education (low vs. high) (OR 1.5, 95%CI 1.2–1.9) and low household income (low vs. high) (OR 1.7, 95%CI 1.3–2.3) were associated with absence of lifetime screening. Having a religious affiliation (OR 1.3, 95%CI 1.1–1.5) and never being married/lived in common-law (OR 1.5, 95%CI 1.2–1.9) were also associated with never having undergone screening. Notably, not having a family physician was an important contributing factor (OR 2.3, 95%CI 1.6–3.3). However, of participants who never underwent a pap test, 97% reported having a family physician.

Conclusion/Implications Our analysis highlights inequities in access to cervical cancer screening in the Canadian context. This data can help inform targeted education and empowerment strategies to increase cancer screening uptake.

PR086/#488 CAN HPV SELF SAMPLING BE USED FOR CERVICAL CANCER SCREENING IN INDIA?

Gauravi Mishra*, Shamilla Pimple, Pavita Anand, Vasundhara Kulkarni, Sanjay Biswas, Aril Patil. Tata Memorial Hospital, Preventive Oncology, Mumbai, India

Introduction Evidence from high income countries supports HPV-self sampling (HPV-SS) for improving cervical cancer screening coverage. Success of HPV-Self sampling (HPV-SS) in resource constrained countries like India with diverse population, will depend on developing impactful health education material, generating awareness towards cervical cancer and HPV-SS and on precision in performing test by beneficiaries. The current study was undertaken with objectives to determine knowledge, attitudes and practices (KAP), acceptability, barriers, agreement rates and prevalence of HPV in different population subgroups using varied methods of communication.

Methods The current study enrolled 1600 women in age group of 30–55 yrs, from urban slums (500), urban non-slums (500) and rural (600) settings in Maharashtra, India. Information regarding cervical cancer and steps for collecting self sample was explained by two modalities; health education by trained health personnel in health education arm and through printed pictorial depiction in the pamphlet arm. One sample for HPV testing was collected by health personnel for each participant in both arms.

Results Overall prevalence of HPV was 7.8% with no significant differences across the settings. Overall acceptance of HPV-SS was 98.4%. Awareness regarding cervical cancer and HPV-SS was similar across settings and modalities of education. The overall concordance rates between HPV-SS and health personnel collected sample was 94.8% (k=0.508, CI=0.458–0.559, p<0.001) and was similar across settings. Compliance for clinical assessment of screen positive women and for treatment was 76.8% and 80% respectively.

Conclusion/Implications The study demonstrated that HPV-SS is acceptable, feasible and implementable in India and will assist in improving cervical cancer screening coverage.

PR087/#201 PREVALENCE OF HIGH-RISK HPV DNA IN A SEMI-URBAN POPULATION OF UTTARAKHAND, INDIA USING A POINT-OF-CARE TEST

1Shalri Rajaram*, 2Shilpa Panta, 3Ayush Hed, 4Ajeet Singh Bhadoria, 5Latika Chawla, 6Himani Bhan, 7Varsha Kamath, 8Neevetha Ravechandran, 9Jaya Chaturvedi. 1All India Institute of Medical Sciences, Rishikesh, Gynecologic Oncology (Obstetrics and Gynecology), Rishikesh, India; 2AllIMS Rishikesh, Obst, Rishikesh, India; 3AllIMS Rishikesh, Community and Family Medicine, Rishikesh, India; 4All India Institute of Medical Sciences, Rishikesh, Obstetrics and Gynecology, Rishikesh, India

Introduction WHO recommends a framework shift from screening with cytology and visual inspection methods, to detection of HPV DNA as the primary screening test and, endorses vaginal self-sampling as method of collection. This study was planned with the objective to determine the prevalence of HR-HPV 16/31 & 18/45 in vaginal samples using a real-time micro-PCR analyzer and to study the acceptability of self-sampling.

Methods Micro-PCR test (Truenat®) was used on vaginal samples collected by self-sampling for detection of HR-HPV infections 16/31,18/45. A sample size of 975 women was calculated with 95% confidence, 20% relative precision and adjusting for 10% non-responder rate. Samples were collected in the community during Covid-19 pandemic. Prevalence of HR-HPV 16,18 was determined separately by RT-PCR using HPV-Q Real-time PCR kit (genes2me).

Results Of 975 eligible women screened, prevalence was 4.6% with 45 women testing positive for HR-HPV (16,31,18,45). Of these 60% were confirmed positive for HR-HPV 16 & 18 by RT-PCR. Of the 45 positive women, 22(48.9%) underwent colposcopy and treated accordingly while the rest declined.
Abstracts

PR088/#198 EZH2/EZH1 INHIBITOR TULMIMETOSTAT (CPI-0209): PRELIMINARY PHASE II RESULTS AND FIRST BIOMARKER FINDINGS IN PATIENTS WITH ARID1A-MUTANT OVARIAN CLEAR CELL OR ENDOMETRIAL CARCINOMAS (OCCC/EC)

Introduction ARID1A mutation (ARID1Amut) has a high incidence in OCCC (up to 60%) and EC (up to 40%), with evidence as a negative prognostic marker for treatment resistance and outcomes. EZH2 inhibition in ARID1Amut solid tumors results in tumor growth inhibition (Bitler et al. Nat Med 2015;21:231–238). Preliminary Phase II (NCT04104776) efficacy, safety, and biomarker findings from OCCC and EC cohorts receiving tulmimetostat are reported.

Methods The Phase II study is evaluating tulmimetostat 350 mg once daily in 6 disease-based cohorts, including ARID1Amut OCCC/EC. Per Simon 2-stage design, expansion of enrolment (plus n=19 patients per cohort in Stage 2) requires objective response rate (ORR) ≥1/10 in Stage 1. Primary endpoint is ORR; secondary endpoints include safety. Evaluation of two additional dose levels was implemented for both cohorts, per FDA recommendation of Project Optimus, to inform on optimal tulmimetostat dose.

Results 24 patients were enrolled (OCCC, n=14; EC, n=10); 50% of each cohort have received ≥3 prior treatment lines. Both cohorts are eligible for Stage 2 expansion, with 1 and 2 confirmed partial responses in patients with OCCC and EC, respectively (table 1). The manageable safety profile across all 6 tumor cohorts (n=81) was consistent with known class effects; Grade ≥3 related adverse events (≥10% of patients) included thrombocytopenia, anemia, neutropenia, and diarrhea.

Next generation sequencing did not reveal a specific hotspot for ARID1Amut locations impacting clinical outcome in patients with OCCC/EC.

Conclusion/Implications These preliminary findings in heavily pre-treated patients with ARID1Amut OCCC/EC support continued investigation of tulmimetostat monotherapy.

PR089/#862 ARTIFICIAL INTELLIGENCE-BASED DIAGNOSTIC SYSTEM FOR THE DETECTION OF ABNORMAL COLPOSCOPIC FINDINGS

Introduction Colposcopic examination requires sufficient training to detect cervical intraepithelial neoplasia (CIN) with (1) high diagnostic accuracy and (2) minimizing time and reducing tissue biopsies. This study aimed to develop an artificial intelligence (AI) based system which replicates expert colposcopic examination techniques, independent of examiner skill.

Abstract PR088/#198 Table 1

<table>
<thead>
<tr>
<th>Best responses*</th>
<th>OCCC</th>
<th>EC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy evaluable, n</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Best confirmed response, †</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Best confirmed or unconfirmed response, ‡</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>Not evaluable</td>
<td>Discontinued without response assessment</td>
</tr>
<tr>
<td>CR, complete response; EC, endometrial cancer; OCCC, ovarian clear cell carcinoma; EC, partial response; stable disease, stable evidence.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*data cut-off 14 February 2023; †Per RECIST 1.1; ‡Patient had a radiological assessment (stable disease) prior to the required protocol-specified window (at least 28 days).